Somatosensory impairments in patients with multiple sclerosis: association with dynamic postural control and upper extremity motor function

2020 ◽  
Vol 37 (2) ◽  
pp. 117-124
Author(s):  
Esra Dogru Huzmeli ◽  
Taskin Duman
Keyword(s):  
Multiple Sclerosis ◽  
Postural Control ◽  
Upper Extremity ◽  
Motor Function

Upper Extremity Motor Fatigability as an Early Indicator in Pediatric Onset Multiple Sclerosis

2021 ◽  
pp. 088307382199988
Author(s):  
Giuseppina Pilloni ◽  
Martin Malik ◽  
Raghav Malik ◽  
Lauren Krupp ◽  
Leigh Charvet
Keyword(s):  
Multiple Sclerosis ◽  
Grip Strength ◽  
Upper Extremity ◽  
Static Fatigue ◽  
Healthy Controls ◽  
Fatigue Index ◽  
Left Hand ◽  
Right Hand ◽  
Computer Based ◽  
Pediatric Onset

Aim: To adopt a computer-based protocol to assess grip fatigability in patients with pediatric-onset multiple sclerosis to provide detection of subtle motor involvement identifying those patients most at risk for future decline. Method: Pediatric-onset multiple sclerosis patients were recruited during routine outpatient visits to complete a grip assessment and compared to a group of healthy age- and sex-matched controls. All participants completed a computer-based measurement of standard maximal grip strength and repetitive and sustained grip performance measured by dynamic and static fatigue indices. Results: A total of 38 patients with pediatric-onset multiple sclerosis and 24 healthy controls completed the grip protocol (right-hand dominant). There were no significant group differences in maximal grip strength bilaterally (right: 21.8 vs 19.9 kg, P = .25; left: 20.4 vs 18.7 kg, P = .33), although males with pediatric-onset multiple sclerosis were significantly less strong than healthy controls (right: 26.53 vs 21.23 kg, P = .009; left; 25.13 vs 19.63 kg, P = .003). Both dynamic and static fatigue indices were significantly higher bilaterally in pediatric-onset multiple sclerosis compared with healthy control participants (left-hand dynamic fatigue index: 18.6% vs 26.7%, P = .003; right-hand static fatigue index: 28.3% vs 41.3%, P < .001; left-hand static fatigue index: 31.9% vs 42.6%, P < .001). Conclusion: Brief repeatable grip assessment including measures of dynamic and sustained static output can be a sensitive indicator of upper extremity motor involvement in pediatric-onset multiple sclerosis, potentially identifying those in need of intervention to prevent future disability.

Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis

2011 ◽  
Vol 133 (3) ◽  
pp. 1033-1038 ◽  
Author(s):  
Elena Buccellato ◽  
Donatella Carretta ◽  
Aneli Utan ◽  
Chiara Cavina ◽  
Ester Speroni ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Motor Function

Quantitative assessment of upper extremities motor function in multiple sclerosis

2018 ◽  
Vol 26 ◽  
pp. 647-653 ◽  
Author(s):  
Kristina Daunoraviciene ◽  
Jurgita Ziziene ◽  
Julius Griskevicius ◽  
Jolanta Pauk ◽  
Agne Ovcinikova ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Motor Function ◽  
Quantitative Assessment ◽  
Upper Extremities

scholarly journals Relationship between Physical Disability and Black Holes in Multiple Sclerosis: Upper Extremity Functions - an Important Parameter

2021 ◽  
Vol 1 (1) ◽  
pp. 17-21
Author(s):  
Bilge Piri Cinar ◽  
Gülcan Kalaycı ◽  
Mustafa Acikgoz ◽  
Serkan Ozakbas
Keyword(s):  
Multiple Sclerosis ◽  
Black Holes ◽  
Upper Extremity ◽  
Physical Disability

scholarly journals Predictors of Clinically Important Improvements in Motor Function and Daily Use of Affected Arm after a Botulinum Toxin A Injection in Patients with Chronic Stroke

Toxins ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 13
Author(s):  
Jen-Wen Hung ◽  
Wen-Chi Wu ◽  
Yi-Ju Chen ◽  
Ya-Ping Pong ◽  
Ku-Chou Chang
Keyword(s):  
Botulinum Toxin ◽  
Upper Extremity ◽  
Motor Function ◽  
Botulinum Toxin A ◽  
Change Score ◽  
Toxin A ◽  
Injection Duration ◽  
Active Motor ◽  
Quality Of Movement

Identifying patients who can gain minimal clinically important difference (MCID) in active motor function in the affected upper extremity (UE) after a botulinum toxin A (BoNT-A) injection for post-stroke spasticity is important. Eighty-eight participants received a BoNT-A injection in the affected UE. Two outcome measures, Fugl–Meyer Assessment Upper Extremity (FMA-UE) and Motor Activity Log (MAL), were assessed at pre-injection and after 24 rehabilitation sessions. We defined favorable response as an FMA-UE change score ≥5 or MAL change score ≥0.5.Statistical analysis revealed that the time since stroke less than 36 months (odds ratio (OR) = 4.902 (1.219–13.732); p = 0.023) was a significant predictor of gaining MCID in the FMA-UE. Medical Research Council scale -proximal UE (OR = 1.930 (1.004–3.710); p = 0.049) and post-injection duration (OR = 1.039 (1.006–1.074); p =0.021) were two significant predictors of MAL amount of use. The time since stroke less than 36 months (OR = 3.759 (1.149–12.292); p = 0.028), naivety to BoNT-A (OR = 3.322 (1.091–10.118); p = 0.035), and education years (OR = 1.282 (1.050–1.565); p = 0.015) were significant predictors of MAL quality of movement. The findings of our study can help optimize BoNT-A treatment planning.

Sign in / Sign up

Export Citation Format

Share Document